PMID: 8593026DOI: 10.1128/aac.39.12.2807Dec 1, 1995Paper
Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression.
Antimicrobial Agents and Chemotherapy
Phillip K PetersonC C Chao
Abstract
Mycobacterium tuberculosis accelerates the progression of human immunodeficiency virus type 1 (HIV-1) infection. The results of this study, which show that thalidomide inhibits the upregulation of HIV-1 expression in U1 cells stimulated with mycobacterial lipoarabinomannans, support the rationale behind conducting controlled trials of this immunodeficiency agent with patients dually infected with HIV-1 and M. tuberculosis.
References
Nov 11, 1992·Journal of Neuroimmunology·P K PetersonC C Chao
Feb 1, 1992·AIDS Research and Human Retroviruses·G Poli, A S Fauci
Mar 1, 1992·Infection and Immunity·D ChatterjeeI M Orme
Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
Oct 1, 1988·The Journal of Infectious Diseases·B IsakssonP Putkonen
Apr 1, 1994·The Journal of General Virology·R J ShattockG E Griffin
Jan 1, 1995·The Journal of Infectious Diseases·M GhassemiR M Novak
Oct 1, 1994·Antimicrobial Agents and Chemotherapy·P K PetersonC C Chao
Oct 1, 1995·The Journal of Infectious Diseases·P K PetersonC C Chao
May 1, 1993·The Journal of Clinical Investigation·Y ZhangW N Rom
May 1, 1995·Infection and Immunity·M C Brown, S M Taffet
May 1, 1995·The Journal of Clinical Investigation·Y ZhangW N Rom
Feb 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D L PatersonR J Kemp
Jun 1, 1995·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·P KissingerW Brandon
Jan 1, 1995·American Journal of Respiratory and Critical Care Medicine·C WhalenJ Ellner
Apr 1, 1995·Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association·D J MartinK Keddy
Mar 30, 1994·Biochemical and Biophysical Research Communications·S GollapudiS Gupta
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
Jul 31, 1993·Lancet·J W PapeW D Johnson
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·S MakonkawkeyoonG Kaplan
Jan 1, 1993·The Journal of Infectious Diseases·R S WallisJ J Ellner
May 1, 1993·The Journal of Experimental Medicine·Z ToossiE A Rich
❮ Previous
Next ❯
Citations
Feb 22, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·N P JuffermansT van Der Poll
Oct 19, 2004·Clinical Microbiology Reviews·R Bryan RockPhillip K Peterson
Oct 18, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·C MeierhoferC J Wiedermann
Jul 5, 2005·Expert Opinion on Investigational Drugs·C Grassi
Jan 1, 1997·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·G VanhamJ J Ellner
Apr 7, 1998·The American Journal of Medicine·P KeiserV Vadde
Mar 6, 2012·Journal of Neuroscience Methods·Fabíola C R ZucchiOsvaldo M Takayanagui
Sep 25, 1999·Infection and Immunity·D WoldayS Britton
❮ Previous
Next ❯
Related Concepts
Related Feeds
CRISPR Screens in Drug Resistance
CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.
Related Papers
Memórias do Instituto Oswaldo Cruz
J R Lapa e SilvaJ L Ho
Journal of Neuroimmunology
JangEun LeeZsuzsanna Fabry
The Veterinary Record
W P Jaffe